VTRS Viatris Inc.
Company Analysis
Latest News
🟢 Viatris is trading 4.14% up today after beating EPS estimates and raising 2026 guidance
Viatris is trading up 4.14% at $19.75 on November 6, after its November 5 third-quarter report showed an earnings beat and improved 2026 outlook. - Adjusted...
Viatris beats third quarter 2026 earnings expectations and raises its full-year guidance
Viatris reported third quarter 2026 revenue of $3.75 billion, slightly below expectations, though adjusted EPS of $0.71 exceeded analyst estimates. The company...
Viatris Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
Viatris Inc. is expected to report Q3 2026 revenue of $3.77 billion and adjusted EPS of $0.64, with the stock currently trading near $13.15 against an average...
Viatris Secures FDA Approval for RYZUMVI Eye Drops to Treat Presbyopia
Viatris Inc. announced that the U.S. Food and Drug Administration (FDA) approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) to treat presbyopia in...
🟢 Viatris is trading 4.16% up today amid apparent defensive rotation into healthcare
Viatris is trading at $18.17, up 4.16%, with the gain appearing aligned with a defensive rotation into healthcare. - XLV was up 2.12% during the regular...
Viatris Announces Definitive Agreement to Acquire Pacira BioSciences for $36.50 Per Share
Viatris Inc. has entered into a definitive merger agreement to acquire Pacira BioSciences, Inc. The acquisition will be executed through a cash tender offer...
🟢 Viatris is trading 6.8% up in after-hours trading
Viatris is trading 6.8% higher at $19.04 after-hours, with no fresh company announcement found to explain the move. - Shares closed at $17.83 on September 25,...
Viatris targeted at $25 by Oppenheimer, citing undervalued blockbuster pipeline
Oppenheimer initiated coverage of Viatris Inc. with an outperform rating. The firm set a price target of $25.00 per share. This target represents a substantial...
Viatris Wins Japan Approval for Wakix, a First-of-its-Kind Sleep Drug
Japan’s Ministry of Health, Labour and Welfare approved Viatris’ Wakix (pitolisant) for excessive daytime sleepiness. The treatment is indicated for patients...
Viatris eyes upside as Leerink sets $20 target on raised guidance
Leerink Partners initiated coverage on Viatris Inc. with an Outperform rating. Analysts established a price target of $20 for the global healthcare...
🟢 Viatris is trading 6% up in after-hours trading
Viatris is trading 6.34% up at $17.12 after-hours on August 12, 2026, following a $16.10 regular-session close; searches found no clear company-specific...
🟢 Viatris is trading 4.59% up in pre-market after Q2 earnings beat and raised 2026 guidance
Viatris is trading 4.59% up at $17.04 after its August 6, 2026 second-quarter earnings beat. - Revenue reached $3.8 billion, while adjusted EPS was $0.69,...
🔴 Viatris is trading 4.2% down today as China and supply risks overshadowed earnings beat
Viatris is trading 4.2% down at $16.91 after investors appeared to weigh second-half risks tied to China, supply disruptions, and competition despite...
Viatris's second quarter revenue of $3.8B beat estimates as the company raised its full-year 2026 guidance.
Viatris reported second quarter total revenues of $3.8 billion, a 5% increase year-over-year, and an adjusted EPS of $0.69, up 11%. The company posted a U.S....
Viatris Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Viatris Inc. is expected to report Q2 2026 revenue of $3.66 billion and EPS of $0.62 on August 06, 2026, with the current stock price of $17.63 trading...
Viatris Wins FDA Approval for Gwyn Lo Weekly Contraceptive Patch
Viatris received U.S. Food and Drug Administration (FDA) approval for Gwyn Lo, a once-weekly transdermal contraceptive patch. The low-dose estrogen product...
🟢 Viatris is trading 4.1% up today on healthcare sector strength and pipeline optimism
Viatris is trading at $17.36 (+4.1%), extending its multi-day uptrend despite a weaker broader market. • The move is largely driven by a rally in healthcare...
Viatris Enters ¥40 Billion Amended and Restated Term Loan Credit Agreement
Viatris Inc. has entered into an amended and restated term loan credit agreement, establishing a ¥40 billion senior unsecured term loan facility. The proceeds...
Viatris reports 33% protein reduction in Phase 3 Japan kidney trial
Viatris announced positive top-line results from a Phase 3 trial of VR-205 in Japanese adults. The drug treats primary immunoglobulin A nephropathy (IgAN), a...
🔴 VTRS is trading 5.1% down today after insider stock sale near 52-week highs
VTRS is trading 5.1% down at $15.50 following an after-hours pullback triggered by headlines regarding an insider stock sale near 52-week highs. • Interim CFO...